Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget imp...

Full description

Bibliographic Details
Main Authors: Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter, Minyoung Jang
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Health Services Research
Subjects:
Inflammatory bowel disease
Ulcerative colitis
Crohn’s disease
Budget impact
Online Access:https://doi.org/10.1186/s12913-022-08683-y

Internet

https://doi.org/10.1186/s12913-022-08683-y

Similar Items